Of interest, Chen et al. [166] demonstrated that hepcidin overexpression in animal models of hepatic steatosis results in attenuation of steatosis, indicating that patients with both iron overload and hepatic steatosis may benefit from hepcidin-based therapy. The gene discussed is HAMP; the disease is steatosis.